Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy - Related Studies

Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy

This study is ongoing, but not recruiting participants.

Study NCT00004249. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lung Cancer

2	Additional conditions recognized in this trial
		Carcinoma, Small Cell
		Lung Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Carcinoma
		Carcinoma, Neuroendocrine
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Thoracic Neoplasms

4	Interventions listed in this trial
		QS21
		keyhole limpet hemocyanin
		polysialic acid

5	Additional drug interventions recognized in this trial
		Keyhole-limpet hemocyanin
		QS 21

6	More general drug interventions related to this trial
		Adjuvants, Immunologic
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs

7	Sponsors listed in this trial
		Memorial Sloan-Kettering Cancer Center
		National Cancer Institute (NCI)